Hepatic Antifibrotic Pharmacotherapy:Are We Approaching Success?

Yue Chang; Hai Li

首页> 外文期刊>临床与转化肝病杂志（英文版） >Hepatic Antifibrotic Pharmacotherapy:Are We Approaching Success?

【24h】

Hepatic Antifibrotic Pharmacotherapy:Are We Approaching Success?

机译：肝抗灰度药物治疗：我们是否接近成功？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相关主题

摘要

The incidence rate and mortality of liver fibrosis caused by various etiologies are high throughout the world. Liver fibrosis, the subsequent cirrhosis and other serious related complications threaten the health of patients and represent a serious medical burden;yet, there is still a lack of approved methods to prevent or reverse liver fibrosis. Therefore, effective hepatic antifibrotic drugs are urgently needed. The activation and proliferation of hepatic stellate cells are still the mechanisms of fibrosis that remain the focus of therapeutic research. In recent years, significant progress has been made in the development and applicability of antifibrosis drugs. In this review, we summarize the effectiveness and safety of available antifibrosis drugs utilizing different targets. In addition, some characteristics of antifibrosis drugs in phase II and III trials are introduced in detail.

著录项

来源
《临床与转化肝病杂志（英文版）》 |2020年第2期|P.222-229|共8页
作者
Yue Chang; Hai Li;
展开▼
作者单位

Division of Gastroenterology and Hepatology Tianjin Xiqing Hospital Tianjin ChinaTianjin Key Laboratory of Hepatopancreatic Fibrosis and Molecular Diagnosis and Treatment Tianjin China;

Division of Gastroenterology and Hepatology Tianjin Xiqing Hospital Tianjin ChinaTianjin Key Laboratory of Hepatopancreatic Fibrosis and Molecular Diagnosis and Treatment Tianjin China;

展开▼
收录信息
原文格式 PDF
正文语种 chi
中图分类消化系及腹部疾病;
关键词
Antifibrotic agents; Fibrosis; Liver; Reversal; Pharmacotherapy;

Hepatic Antifibrotic Pharmacotherapy:Are We Approaching Success?

摘要

著录项

相关主题

期刊订阅